| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $21,770,934 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS122777 | Targeting mitochondrial Complex I in neonatal hypoxia-ischemia | 000 | 5 | NIH | 2/5/2026 | $459,576 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R00DK131018 | Unravelling the Role of Epigenetics and Cytokines in Type 2 Diabetes among African-ancestry Populations | 000 | 4 | NIH | 12/18/2025 | $242,695 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R00CA273171 | Investigating the role of neddylation in the repair of topoisomerase I inhibitor-induced replication damage in colorectal cancer | 000 | 3 | NIH | 12/5/2025 | $224,100 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K01AI168587 | Systems Vaccinology Approaches to Define and Predict Immunity in Response to Nontyphoidal Salmonella Conjugate Vaccines | 000 | 5 | NIH | 1/27/2026 | $129,222 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | F31DA062453 | The Impact of Perinatal Fentanyl on Dopamine Neuron Circuitry and Behavior | 000 | 2 | NIH | 12/19/2025 | $46,528 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | F30EY035154 | Combining OCE and Brillouin microscopy to evaluate in vivo lens biomechanics in Presbyopia | 000 | 4 | NIH | 1/20/2026 | $54,538 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | DP2AI192747 | Gut Microbial Protein Metabolism in Food Allergy and Oral Immunotherapy Efficacy | 000 | 1 | NIH | 1/28/2026 | $466,500 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01MH131566 | Reward, Salience and Value Processing in Youths at Risk for Psychosis: The RSVP Study | 000 | 3 | NIH | 1/21/2026 | $790,425 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS117102 | Stem Cell Surface Modification to Promote Nerve Regeneration | 000 | 5 | NIH | 12/18/2025 | $386,953 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS120930 | Molecular basis for adenosine A3 receptor agonists in the treatment of migraine | 000 | 5 | NIH | 12/18/2025 | $425,628 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HD108705 | Intersection of the mTOR/p70S6K1 signaling and the HIPPO-Yap tissue organizer in neurulation and diabetic embryopathy | 000 | 4 | NIH | 1/23/2026 | $586,642 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL166402 | Targeting a Defined Surgical Stress-Induced Inflammatory Pathway to Improve Peri-Operative Outcomes | 000 | 4 | NIH | 1/30/2026 | $531,931 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK109581 | Assessment of Donor Quality for Improving Kidney Transplant Outcomes | 000 | 8 | NIH | 1/28/2026 | $618,786 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK133421 | Axin Stabilization by Novel Small Molecules to Treat Non-alcoholic Steatohepatitis | 000 | 4 | NIH | 12/30/2025 | $538,952 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK130238 | Pharmacogenetics of the Response to a GLP1R Agonist | 000 | 5 | NIH | 12/4/2025 | $672,063 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA273216 | Targeting polo-like kinase 1 (PLK1) for treatment of small cell lung cancer | 000 | 5 | NIH | 12/24/2025 | $581,504 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA269995 | Nanotherapeutic enhancement of interstitial thermal therapy for glioblastoma | 000 | 4 | NIH | 1/7/2026 | $571,318 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DC012564 | Usher Proteins in the Inner ear Structure and Function | 000 | 14 | NIH | 1/21/2026 | $560,296 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA290796 | An engineered prodrug for inhibition of cancer growth and metastasis | 000 | 2 | NIH | 12/23/2025 | $389,640 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA279108 | The pro-metastatic role of androgen receptor in estrogen receptor mutated breast cancer | 000 | 3 | NIH | 12/22/2025 | $558,043 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA298839 | Tumor-associated pDC (TApDC) in liver cancer with HIV infection | 000 | 2 | NIH | 12/11/2025 | $570,655 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA292106 | Chemotherapy induced MASP activation and ovarian cancer metastasis | 000 | 2 | NIH | 1/13/2026 | $415,963 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA285468 | First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers | 000 | 3 | NIH | 12/22/2025 | $577,013 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK074797 | Inter-organ signaling in heme metabolism and organismal homeostasis. | 000 | 15 | NIH | 12/30/2025 | $397,410 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI176333 | New roles of IFN-inducible OAS proteins in innate immune defense against bacterial infections | 000 | 4 | NIH | 12/18/2025 | $597,100 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI183599 | Genomic surveillance for artemisinin resistance in Africa: moving beyond a candidate gene approach | 001 | 2 | NIH | 1/16/2026 | $45,339 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI183599 | Genomic surveillance for artemisinin resistance in Africa: moving beyond a candidate gene approach | 000 | 2 | NIH | 1/14/2026 | $714,997 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI175439 | Anti-flavivirus B cell response analysis to aid vaccine design | 000 | 4 | NIH | 1/23/2026 | $770,979 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AR083363 | Lipid metabolism in the growth plate | 000 | 3 | NIH | 11/25/2025 | $482,145 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI190438 | Development of Oral Immunotherapy against Clostridioides difficile Transmission | 000 | 2 | NIH | 1/28/2026 | $719,022 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AG081693 | Deep-Learning Enhanced ASL MRI For Early AD Assessment | 000 | 3 | NIH | 12/11/2025 | $682,656 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AG089369 | Normalized cerebrovascular reactivity MRI in small-vessel-disease (SVD) related cognitive impairment | 000 | 1 | NIH | 1/20/2026 | $589,154 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI172487 | Broadly neutralizing antibody combinations with single virions in HIV+ plasma | 000 | 4 | NIH | 12/19/2025 | $386,250 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI167947 | Pertussis inflammation is mediated by a balance between peptidoglycan recognition proteins-1 and -4 | 000 | 5 | NIH | 1/22/2026 | $386,250 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI168192 | Mechanisms coordinating the local and systemic resistance to pathogens | 000 | 4 | NIH | 11/26/2025 | $565,170 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI172827 | Multi-Omics Characterization of Plasmodium Vivax Hypnozoites | 001 | 4 | NIH | 1/8/2026 | $121,824 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI172827 | Multi-Omics Characterization of Plasmodium Vivax Hypnozoites | 000 | 4 | NIH | 1/6/2026 | $553,943 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UM1AI148689 | Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | 000 | 7 | NIH | 12/18/2025 | $617,961 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UM1AI148689 | Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | 000 | 7 | NIH | 12/18/2025 | $309,697 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U18FD007054 | Center for Research on Complex Generics | 002 | 5 | FDA | 1/6/2026 | $1,500,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UC2CA293782 | Community-led Research Project (CRP) Hub at UMB | 000 | 2 | NIH | 1/8/2026 | $1,965,002 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R37MH080046 | Internal Dynamics of the Postsynaptic Density | 000 | 19 | NIH | 12/23/2025 | $679,801 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R25DE032530 | Maryland Program in Dental Research Experience (D-REX) | 000 | 4 | NIH | 1/13/2026 | $135,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R35GM144147 | Photonics-based Fluorescence Imaging for Research, Diagnostics, and Pathology | 000 | 5 | NIH | 1/26/2026 | $347,625 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R35GM156369 | Conformational Dynamics and Regulatory Mechanisms in the KCNH Family of Ion Channels | 000 | 2 | NIH | 12/24/2025 | $384,863 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AI196697 | A cord-blood specific subset of human gamma-delta T cells with distinct functional features | 000 | 1 | NIH | 2/3/2026 | $455,500 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R00HD115830 | Neural Markers of Developmental Delays in Premature and Full Term Infants | 000 | 3 | NIH | 1/29/2026 | $249,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS129502 | Role of reactive astrocytes in prion diseases | 000 | 4 | NIH | 12/9/2025 | $560,291 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AG070072 | Brain-selective estrogen therapy for menopausal hot flushes in an advanced translational animal model | 000 | 5 | NIH | 10/7/2025 | $0 |
|
